Evidence map›Paper›PMID 27487401›Full record

ArticleJAMA cardiology2016

Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes.

Jon White, Daniel I Swerdlow, David Preiss, Zammy Fairhurst-Hunter, Brendan J Keating, Folkert W Asselbergs, Naveed Sattar, Steve E Humphries, Aroon D Hingorani, Michael V Holmes

Open access · hybridAbstract read
In one paragraph

Article in JAMA cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 13 pooled it
32.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

168 citing papers in PubMed, 13 syntheses or guidelines pooled it, 314 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

108 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 3 countries.

Jon WhiteUniversity College London Genetics Institute, University College London, London, England.
Daniel I SwerdlowFarr Institute at University College London, London, England3Department of Medicine, Imperial College London, London, England.
David PreissClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England.
Zammy Fairhurst-HunterThe Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, England.
Brendan J KeatingCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 7Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania.
Folkert W AsselbergsDivision of Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands9Durrer Center for Cardiovascular Research, Netherlands Heart Institute, Utrecht, Netherlands10Institute of Cardiovascular Science, University College London, London, England.
Naveed SattarInstitute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, Scotland.
Steve E HumphriesCardiovascular Genetics, British Heart Foundation Laboratories, Institute Cardiovascular Science, University College London, London, United Kingdom.
Aroon D HingoraniFarr Institute at University College London, London, England10Institute of Cardiovascular Science, University College London, London, England.
Michael V HolmesClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England.
Farr Institute · GBUniversity of Oxford · GBBritish Heart Foundation · GBCentre for Human Genetics · GBChildren's Hospital of Philadelphia · USUniversity College London · GBUniversity Medical Center Utrecht · NLUniversity of Glasgow · GB

Funding

British Heart Foundation PG08/008British Heart Foundation RG/10/12/28456Medical Research Council G0802432Medical Research Council MR/K006584/1Wellcome Trust
6 · The paper itself

Abstract

importanceLow-density lipoprotein cholesterol (LDL-C) is causally related to coronary artery disease (CAD), but the relevance of high-density lipoprotein cholesterol (HDL-C) and triglycerides (TGs) is uncertain. Lowering of LDL-C levels by statin therapy modestly increases the risk of type 2 diabetes, but it is unknown whether this effect is specific to statins.

objectiveTo investigate the associations of 3 routinely measured lipid fractions with CAD and diabetes through mendelian randomization (MR) using conventional MR and making use of newer approaches, such as multivariate MR and MR-Egger, that address the pleiotropy of genetic instruments where relevant. DESIGN, SETTING, AND

participantsPublished data from genome-wide association studies were used to construct genetic instruments and then applied to investigate associations between lipid fractions and the risk of CAD and diabetes using MR approaches that took into account pleiotropy of genetic instruments. The study was conducted from March 12 to December 31, 2015. MAIN OUTCOMES AND MEASURES: Coronary artery disease and diabetes.

resultsGenetic instruments composed of 130 single-nucleotide polymorphisms (SNPs) were used for LDL-C (explaining 7.9% of its variance), 140 SNPs for HDL-C (6.6% of variance), and 140 SNPs for TGs (5.9% of variance). A 1-SD genetically instrumented elevation in LDL-C levels (equivalent to 38 mg/dL) and TG levels (equivalent to 89 mg/dL) was associated with higher CAD risk; odds ratios (ORs) were 1.68 (95% CI, 1.51-1.87) for LDL-C and 1.28 (95% CI, 1.13-1.45) for TGs. The corresponding OR for HDL-C (equivalent to a 16-mg/dL increase) was 0.95 (95% CI, 0.85-1.06). All 3 lipid traits were associated with a lower risk of type 2 diabetes. The ORs were 0.79 (95% CI, 0.71-0.88) for LDL-C and 0.83 (95% CI, 0.76-0.90) for HDL-C per 1-SD elevation. For TG, the MR estimates for diabetes were inconsistent, with MR-Egger giving an OR of 0.83 (95%CI, 0.72-0.95) per 1-SD elevation. CONCLUSIONS AND RELEVANCE: Routinely measured lipid fractions exhibit contrasting associations with the risk of CAD and diabetes. Increased LDL-C, HDL-C, and possibly TG levels are associated with a lower risk of diabetes. This information will be relevant to the design of clinical trials of lipid-modifying agents, which should carefully monitor participants for dysglycemia and the incidence of diabetes.

Indexed as

Cholesterol, HDLCholesterol, LDLCoronary Artery DiseaseDiabetes Mellitus, Type 2Genome-Wide Association StudyHumansLipidsPolymorphism, Single NucleotideRisk FactorsCholesterol, HDLCholesterol, LDLLipids

Identifiers

PMID27487401
PMCPMC5642865
OpenAlexW2481252033

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.